In the medical field, the status quo of new drugs that have received much attention is like the chip industry in China. According to the data, by the end of 2017, China registered 2,571 clinical studies, accounting for only 2.2% of the world's total, of which 1,334 were completed, accounting for only 1.71% of the world, and there is still a big gap with developed countries such as the United States.
Now, despite the increasing attention of experts from various circles, such as the government, enterprises, and research institutes, policy support, capital favor, and corporate efforts are all promoting the development of innovative drugs in China. However, in the process of development, China is still facing the status quo of insufficient research.
If medical research is a "bullet" in the technical dispute, stable isotope products are an indispensable "raw material".
It must be pointed out that even the raw materials such as stable isotope, China's major research institutes must rely heavily on imports. To a certain extent, this is also an important reason for the development of new drug research in China.
Nanjing Green is just a member of the break-up. They have broken the international monopoly of stable isotope products with their own technological advantages.
The domestic market is in short supply, and Nanjing’s green ambition is bound to
Speaking of stable isotopes, its application fields are very extensive. In addition to the medical field, it is also far-reaching in the fields of life science, environmental science, agricultural research, analysis and testing.
Taking diabetes as an example, the disease is an endocrine and metabolic disease characterized by abnormal glucose metabolism. It usually manifests as a whole metabolic disorder (including sugar, lipid, amino acid metabolism disorder, etc.). Therefore, it is very suitable for the application of stable isotope. Trace the technology to understand the ins and outs of metabolites. Similarly, in the field of in vitro detection, stable isotope tracing techniques are widely used because of their high precision.
However, with the increasing demand in many fields such as pharmaceutical R&D and testing, the current situation of the stable isotope market is in short supply. However, due to the high technical barriers of the product, there is no upstream R&D provider in the stable isotope product industry chain. Even in the international arena, there are only a few established companies.
As pointed out by Nanjing Green CEO, stable isotope research and development costs are high, technically difficult, and can not follow the existing mature preparation methods, must be developed from zero design. So even though this market is a blue ocean, many companies are reluctant to do it, and there is no way to start.
Thanks to the deep accomplishments of the two founders in the field of biochemistry, Nanjing Green is a unique approach in this respect. It uses innovative technology to break through the barriers and achieve its own barriers to competition.
High quality and low price, hitting international monopoly
In the industry of stable isotope, there are widespread problems such as high price, good quality and long product cycle.
This is true in any industry. Once the manufacturer is in a monopoly position, that is, some companies have a large market share. When they can determine the output and manipulate the price of the product, in order to maximize their own interests, in the general quality situation. Next, the price is higher is a natural thing. The same is true for the stable isotope field.
He said that he was deeply hurt when he was reading Bo. At that time, because many isotopes were too expensive, they could not afford it and brought some resistance to their research projects.
In order to reduce costs, Nanjing Green has subverted the traditional chemical synthesis method in the production process, using innovative plant transformation methods. This technological improvement and innovation brings tangible advantages: cost reduction. Therefore, its product pricing only needs half of similar products.
In addition, he also pointed out that because the company is small in size, compared with the large international companies, Nanjing Green has a certain advantage in terms of manpower and material cost.
At the same time, the new production process also simplifies the production process, and the product cycle is naturally shortened. To a certain extent, this has brought competitiveness to Nanjing Green.
However, in order to maximize the competitive advantage, Nanjing Green has also spent a lot of thought on product quality. Under the condition of guaranteeing certain costs, they broke the calibration rate of 95% of stable isotope products, and it has reached 98%.
The three major market directions of Nanjing Green
Despite its establishment, Nanjing's unique technology soon won the favor of Zhongke Chuangxing. In February 2018, it successfully completed the first round of financing of several million yuan. Undoubtedly, this means that its technical level and business model have officially been recognized by capital. In less than three months, at the 31st Annual Meeting of the Chinese Chemical Society, the company officially unveiled its mature products.
At present, these mature product lines also reflect their main market orientation:
Raw materials: more than 500 stable isotope small molecule synthesis blocks (including 2H, 13C, 15N labeled small molecule compounds, such as fine chemicals such as alkanes, alkenes, alcohols, aldehydes, acids, etc.);
Analytical test class: a new type of nuclear magnetic resonance solvent (breaking the solubility limit of common nuclear magnetic solvent from the source);
High-end customized products: custom synthesis of stable isotope-labeled drug molecules (for drug analysis, drug metabolism, pharmacological studies, medical diagnostics, residue analysis, etc.).
For example, Cefpodoxime D3, which is developed by 昊绿, is an upgrade for the broad-spectrum third-generation cephalosporin (ceftomel), which is mainly used to treat pneumonia, acute bronchitis, and throat caused by sensitive bacteria. Inflammation and other diseases. Now, 昊 Green will use technological improvements to extend the half-life of its new drug in the body and improve bioavailability.
Of course, they said that in the future, they will gradually enrich their product lines to meet the research and development needs of more fields.
Conclusion
In the first show of Nanjing Green's exhibition, its products received very good response, and also attracted the attention of teachers and students in domestic research institutes, especially the research scholars and teachers of universities, such as the relevant laboratory teachers of Shanxi University. A solvent product was placed on the spot.
Insulin Syringes Needle,Disable Syringe,Monoject Syringe,10 Ml Syringe
FOSHAN PHARMA CO., LTD. , https://www.fospharma.com